After discussing currently available evidence regarding adjuvant chemotherapy in the treatment of rectal cancer, Francesco Sclafani explains how to select patients with rectal cancer who could benefit from it. He insists on the importance of doctor-patient discussion in the absence of robust data.
In conclusion, he suggests a change in the way of designing clinical trials in the rectal cancer setting in the future and expresses the need for predictive biomarkers identification.

Permissions:
Reprinted from Cochrane Database Syst Rev. 2012 Mar; 2012(3): CD004078.
Reprinted from Lancet Oncol. 2014 Oct;15(11):1245-53, Copyright (2014), with permission from Elsevier.
Reprinted from Brown G, et al., Radiology 2003;227:371-377. Copyright (2003), with permission from RSNA.
Reprinted from MERCURY Study Group, Radiology 2007;243:132-139. Copyright (2007), with permission from RSNA.
Reprinted from Ann Surg Oncol. 2012 Jul;19(7):2212-23, Copyright (2012), with permission from Springer.

Produced by the European Society for Medical Oncology (ESMO) - OncologyPRO.esmo.org

свернуть